| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2,5-Dichloropyridine is a synthetic intermediate and building block used in pharmaceutical and agrochemical synthesis. As a building block, it does not have specific biological receptors as its primary targets. The compound has been used to synthesize 4-benzodiazepine-2,5-diones as Hdm2 antagonists and inhibitors of ERK protein kinase. The two chlorine substituents provide handles for selective nucleophilic aromatic substitution and cross-coupling reactions, enabling the synthesis of diverse 2,5-substituted pyridine compounds. Its primary applications are as a synthetic intermediate for drug discovery.
|
|---|---|
| ln Vitro |
In vitro, 2,5-dichloropyridine is used as a biochemical reagent and organic compound for biomedical research. It is a versatile building block in the preparation of various pharmaceutical and biologically active compounds. It has been used to synthesize 4-benzodiazepine-2,5-diones as Hdm2 antagonists and inhibitors of ERK protein kinase. Cellular assays are typically performed on the final compounds synthesized from this building block. The compound's dichlorinated pyridine scaffold allows for various chemical transformations, making it valuable for drug discovery and chemical synthesis.
|
| ln Vivo |
In vivo data for 2,5-dichloropyridine is limited, as it is primarily a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. However, Hdm2 antagonists and ERK inhibitors synthesized using this building block have been investigated for their therapeutic potential in cancer. The compound's primary value lies in its use as a synthetic intermediate for preparing various pharmaceuticals. Specific in vivo data for the parent compound is not available in the public literature.
|
| Enzyme Assay |
In vitro enzyme assays for 2,5-dichloropyridine are not typically performed, as it is primarily a synthetic intermediate. The compound is used as a building block in the synthesis of Hdm2 antagonists and ERK inhibitors. A typical assay involves using the compound in chemical reactions, including selective nucleophilic aromatic substitution and cross-coupling reactions. The compound is dissolved in organic solvents such as DMSO or THF. The resulting products can be evaluated for biological activity. Kinase inhibition assays with purified ERK or binding assays for Hdm2 can be performed on the final synthesized compounds. IC₅₀ or binding affinity values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 2,5-dichloropyridine derivatives typically evaluate Hdm2 antagonist or ERK inhibitory activity. A standard protocol involves culturing cancer cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with synthesized compounds at varying concentrations for 24-72 hours. Cell viability is assessed using MTT or similar assays. Hdm2 antagonism is evaluated by measuring p53 activation or downstream target expression by Western blot or ELISA. ERK inhibition is assessed by measuring phosphorylation of downstream targets. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for 2,5-dichloropyridine are not standard, as it is a synthetic intermediate rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would typically be conducted on the final Hdm2 antagonists or ERK inhibitors synthesized using this building block. These studies would evaluate efficacy in cancer models, pharmacokinetics, and safety. The compound's primary value lies in its use as a synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2,5-dichloropyridine is limited, as it is primarily a research reagent. The compound has a molecular weight of 147.99 g/mol and a molecular formula of C₅H₃Cl₂N. It is a solid at room temperature with a melting point of 59-62°C and a boiling point of 190-191°C. It is insoluble in water and has a pKa of -2.25±0.10. The compound is stored in an inert atmosphere at room temperature. As a chlorinated pyridine, it may undergo metabolic dehalogenation and oxidation. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
2,5-Dichloropyridine is classified as a hazardous substance with signal word "Warning". Hazard statements include H315 (Causes skin irritation), H319 (Causes serious eye irritation), and H335 (May cause respiratory irritation). It has Hazard Codes Xi, Xn with Risk Statements R36/37/38 and R22. Safety Statements include S26, S37/39, and S36. It is classified as UN2811, Hazard Class 6.1, and Storage Class 11. Standard safety precautions include handling with appropriate PPE in a well-ventilated area.
|
| Additional Infomation |
2,5-Dichloropyridine (CAS 16110-09-1) is a biochemical reagent with the molecular formula C₅H₃Cl₂N. It is a dihalogenated heteroaromatic building block used in the synthesis of pharmaceuticals, including Hdm2 antagonists and ERK inhibitors. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C5H3CL2N
|
|---|---|
| Molecular Weight |
147.99
|
| Exact Mass |
146.964
|
| CAS # |
16110-09-1
|
| PubChem CID |
27685
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
186.6±20.0 °C at 760 mmHg
|
| Melting Point |
59-62 °C(lit.)
|
| Flash Point |
83.1±7.4 °C
|
| Vapour Pressure |
0.9±0.3 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
2.17
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
76.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=C([H])N=C(C([H])=C1[H])Cl
|
| InChi Key |
GCTFDMFLLBCLPF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3Cl2N/c6-4-1-2-5(7)8-3-4/h1-3H
|
| Chemical Name |
2,5-dichloropyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7572 mL | 33.7861 mL | 67.5721 mL | |
| 5 mM | 1.3514 mL | 6.7572 mL | 13.5144 mL | |
| 10 mM | 0.6757 mL | 3.3786 mL | 6.7572 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
